Journal of Lipid Research, Vol 31, 1911-1924, Copyright © 1990 by Lipid Research, Inc.

ARTICLES

A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes

Y Ikeda, A Takagi, Y Ohkaru, K Nogi, T Iwanaga, S Kurooka and A Yamamoto
Department of Etiology and Pathophysiology, National Cardiovascular Center Research Institute, Osaka, Japan.

We have developed a sandwich-enzyme immunoassay (EIA) for the quantification of lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) in human postheparin plasma (PHP) using monoclonal antibodies (MAbs) directed against the corresponding enzymes purified from human PHP. The sandwich-EIA for LPL was performed by using the combination of two distinct types of anti-LPL MAbs that recognize different epitopes on the LPL molecule. The immunoreactive mass of LPL was specifically measured using a beta-galactosidase-labeled anti-LPL MAb as an enzyme-linked MAb, an anti-LPL MAb linked with the bacterial cell wall as an insolubilized MAb, and purified human PHP-LPL as a standard. The sandwich-EIA for HTGL was carried out by using two distinct anti-HTGL MAbs that recognize different epitopes on HTGL. The limit of detection was 20 ng/ml for LPL and 60 ng/ml for HTGL. Each method yielded a coefficient of variation of less than 6% in intra- and inter-assays, and a high concentration of triglyceride did not interfere with the assays. The average recovery of purified human PHP- LPL and -HTGL added to human PHP samples was 98.8% and 97.5%, respectively. The immunoreactive masses of LPL and HTGL in PHP samples, obtained at a heparin dose of 30 IU/kg, from 34 normolipidemic and 20 hypertriglyceridemic subjects were quantified by the sandwich-EIA. To assess the reliability of the measured mass values, they were compared with the corresponding enzyme activities measured by selective immunoinactivation assay using rabbit anti-human PHP-LPL and -HTGL polyclonal antisera. Both assay methods yielded a highly significant correlation in either normolipidemic (r = 0.945 for LPL; r = 0.932 for HTGL) or hypertriglyceridemic subjects (r = 0.989 for LPL; r = 0.954 for HTGL). The normal mean (+/- SD) level of lipoprotein lipase mass and activity in postheparin plasma was 223 +/- 66 ng/ml and 10.1 +/- 2.9 mumol/h per ml, and that of hepatic triglyceride lipase mass and activity was 1456 +/- 469 ng/ml and 26.4 +/- 8.7 mumol/h per ml, respectively. The present sandwich-enzyme immunoassay methods make it possible to study the molecular nature of LPL and HTGL in PHP from patients with either primary or secondary hyperlipoproteinemia.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M.-E. Paradis, K. O. Badellino, D. J. Rader, A. Tchernof, C. Richard, V. Luu-The, Y. Deshaies, J. Bergeron, W. R. Archer, P. Couture, et al. Visceral Adiposity and Endothelial Lipase J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3538 - 3543. [Abstract] [Full Text] [PDF]

				M.-a. Kawashiri, T. Higashikata, M. Mizuno, M. Takata, S. Katsuda, K. Miwa, T. Nozue, A. Nohara, A. Inazu, J. Kobayashi, et al. Long-Term Course of Lipoprotein Lipase (LPL) Deficiency Due to Homozygous LPLArita in a Patient with Recurrent Pancreatitis, Retained Glucose Tolerance, and Atherosclerosis J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6541 - 6544. [Abstract] [Full Text] [PDF]

				J. Wakai, A. Takagi, M. Nakayama, T. Miya, T. Miyahara, T. Iwanaga, S. Takenaka, Y. Ikeda, and M. Amano A novel method of identifying genetic mutations using an electrochemical DNA array Nucleic Acids Res., October 21, 2004; 32(18): e141 - e141. [Abstract] [Full Text] [PDF]

				M.-C. Beauchamp, S.-E. Michaud, L. Li, M. R. Sartippour, and G. Renier Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression J. Lipid Res., September 1, 2004; 45(9): 1749 - 1757. [Abstract] [Full Text] [PDF]

				T. Koike, J. Liang, X. Wang, T. Ichikawa, M. Shiomi, G. Liu, H. Sun, S. Kitajima, M. Morimoto, T. Watanabe, et al. Overexpression of Lipoprotein Lipase in Transgenic Watanabe Heritable Hyperlipidemic Rabbits Improves Hyperlipidemia and Obesity J. Biol. Chem., February 27, 2004; 279(9): 7521 - 7529. [Abstract] [Full Text] [PDF]

				O. Serri, L. Li, F. Maingrette, N. Jaffry, and G. Renier Enhanced Lipoprotein Lipase Secretion and Foam Cell Formation by Macrophages of Patients with Growth Hormone Deficiency: Possible Contribution to Increased Risk of Atherogenesis? J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 979 - 985. [Abstract] [Full Text] [PDF]

				F. Maingrette and G. Renier Leptin Increases Lipoprotein Lipase Secretion by Macrophages: Involvement of Oxidative Stress and Protein Kinase C Diabetes, August 1, 2003; 52(8): 2121 - 2128. [Abstract] [Full Text] [PDF]

				M.-C. Beauchamp and G. Renier Homocysteine Induces Protein Kinase C Activation and Stimulates c-Fos and Lipoprotein Lipase Expression in Macrophages Diabetes, April 1, 2002; 51(4): 1180 - 1187. [Abstract] [Full Text] [PDF]

				M.-C. Beauchamp, E. Letendre, and G. Renier Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholesterolemia J. Lipid Res., February 1, 2002; 43(2): 215 - 222. [Abstract] [Full Text] [PDF]

				M. Ai, A. Tanaka, K. Ogita, M. Sekinc, F. Numano, F. Numano, and G. M. Reaven Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1628 - 1632. [Abstract] [Full Text] [PDF]

				J. Fan, H. Unoki, N. Kojima, H. Sun, H. Shimoyamada, H. Deng, M. Okazaki, H. Shikama, N. Yamada, and T. Watanabe Overexpression of Lipoprotein Lipase in Transgenic Rabbits Inhibits Diet-induced Hypercholesterolemia and Atherosclerosis J. Biol. Chem., October 19, 2001; 276(43): 40071 - 40079. [Abstract] [Full Text] [PDF]

				Y. Ikeda, A. Takagi, Y. Nakata, Y. Sera, S. Hyoudou, K. Hamamoto, Y. Nishi, and A. Yamamoto Novel compound heterozygous mutations for lipoprotein lipase deficiency: a G-to-T transversion at the first position of exon 5 causing G154V missense mutation and a 5' splice site mutation of intron 8 J. Lipid Res., July 1, 2001; 42(7): 1072 - 1081. [Abstract] [Full Text] [PDF]

				A. WAKATSUKI, N. IKENOUE, Y. OKATANI, K. SHINOHARA, K. WATANABE, and T. FUKAYA Lipolytic Enzyme Effect on Small Low-Density Lipoprotein Particles in Women Treated With Estrogen Obstet. Gynecol., March 1, 2001; 97(3): 333 - 337. [Abstract] [Full Text] [PDF]

				S. Westphal, M. Orth, A. Ambrosch, K. Osmundsen, and C. Luley Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids Am. J. Clinical Nutrition, April 1, 2000; 71(4): 914 - 920. [Abstract] [Full Text] [PDF]

				K. A. Dugi, M. J. A. Amar, C. C. Haudenschild, R. D. Shamburek, A. Bensadoun, R. F. Hoyt Jr, J. Fruchart-Najib, Z. Madj, H. B. Brewer Jr, and S. Santamarina-Fojo In Vivo Evidence for Both Lipolytic and Nonlipolytic Function of Hepatic Lipase in the Metabolism of HDL Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 793 - 800. [Abstract] [Full Text] [PDF]

				N. Mero, L. Suurinkeroinen, M. Syvänne, P. Knudsen, H. Yki-Järvinen, and M.-R. Taskinen Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant J. Lipid Res., September 1, 1999; 40(9): 1663 - 1670. [Abstract] [Full Text]

				Y. Hozumi, M. Kawano, T. Saito, and M. Miyata Effect of Tamoxifen on Serum Lipid Metabolism J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1633 - 1635. [Abstract] [Full Text]

				A. P. van Beek, H. H. J. J. van Barlingen, F. C. de Ruijter-Heijstek, H. Jansen, D. W. Erkelens, G. M. Dallinga-Thie, and T. W. A. de Bruin Preferential clearance of apoB-48-containing lipoproteins after heparin-induced lipolysis is modulated by lipoprotein lipase activity J. Lipid Res., February 1, 1998; 39(2): 322 - 332. [Abstract] [Full Text]

				K.-i. Hirano, S. Yamashita, Y. Kuga, N. Sakai, S. Nozaki, S. Kihara, T. Arai, K. Yanagi, S. Takami, M. Menju, et al. Atherosclerotic Disease in Marked Hyperalphalipoproteinemia : Combined Reduction of Cholesteryl Ester Transfer Protein and Hepatic Triglyceride Lipase Arterioscler. Thromb. Vasc. Biol., November 1, 1995; 15(11): 1849 - 1856. [Abstract] [Full Text]

				P. Tornvall, G. Olivecrona, F. Karpe, A. Hamsten, and T. Olivecrona Lipoprotein Lipase Mass and Activity in Plasma and Their Increase After Heparin Are Separate Parameters With Different Relations to Plasma Lipoproteins Arterioscler. Thromb. Vasc. Biol., August 1, 1995; 15(8): 1086 - 1093. [Abstract] [Full Text]

				S. Takahashi, J. Suzuki, M. Kohno, K. Oida, T. Tamai, S. Miyabo, T. Yamamoto, and T. Nakai Enhancement of the Binding of Triglyceride-rich Lipoproteins to the Very Low Density Lipoprotein Receptor by Apolipoprotein E and Lipoprotein Lipase J. Biol. Chem., June 30, 1995; 270(26): 15747 - 15754. [Abstract] [Full Text] [PDF]